当前位置: X-MOL 学术Clin. Gastroenterol. Hepatol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Real-world Effectiveness of Fecal Microbiota Transplantation for First or Second Clostridioides difficile Infection
Clinical Gastroenterology and Hepatology ( IF 11.6 ) Pub Date : 2024-06-11 , DOI: 10.1016/j.cgh.2024.05.038
Sara Ellegaard Paaske 1 , Simon Mark Dahl Baumwall 2 , Tone Rubak 3 , Frederik Hyllested Birn 2 , Nina Rågård 2 , Jens Kelsen 2 , Mette Mejlby Hansen 2 , Lise Svenningsen 4 , Anne Lund Krarup 5 , Christa Marie Culmbach Fernis 6 , Anders Neumann 7 , Anders Bergh Lødrup 8 , Henning Glerup 9 , Lars Vinter-Jensen 10 , Morten Helms 11 , Lise Tornvig Erikstrup 12 , Anne Karmisholt Grosen 13 , Susan Mikkelsen 14 , Christian Erikstrup 13 , Jens Frederik Dahlerup 1 , Christian Lodberg Hvas 1
Affiliation  

infection (CDI) is associated with high mortality. Fecal microbiota transplantation (FMT) is an established treatment for recurrent CDI, but its use for first or second CDI remains experimental. We aimed to investigate the effectiveness of FMT for first or second CDI in a real-world clinical setting. This multi-site Danish cohort study included patients with first or second CDI treated with FMT from June 2019 to February 2023. The primary outcome was cure of associated diarrhea (CDAD) 8 weeks after the last FMT treatment. Secondary outcomes included CDAD cure 1 and 8 weeks after the first FMT treatment and 90-day mortality following positive test. We included 467 patients, with 187 (40%) having their first CDI. The median patient age was 73 years (interquartile range [IQR], 58–82 years). Notably, 167 (36%) had antibiotic-refractory CDI, 262 (56%) had severe CDI, and 89 (19%) suffered from fulminant CDI. Following the first FMT treatment, cure of CDAD was achieved in 353 patients (76%; 95% confidence interval [CI], 71%–79%) at week 1. At week 8, 255 patients (55%; 95% CI, 50%–59%) maintained sustained effect. In patients without initial effect, repeated FMT treatments led to an overall cure of CDAD in 367 patients (79%; 95% CI, 75%–82%). The 90-day mortality was 10% (95% CI, 8%–14%). Repeated FMT treatments demonstrate high effectiveness in managing patients with first or second CDI. Forwarding FMT in CDI treatment guidelines could improve patient survival. , Number:

中文翻译:


粪便微生物群移植治疗第一次或第二次艰难梭菌感染的真实效果



感染(CDI)与高死亡率相关。粪便微生物移植 (FMT) 是治疗复发性 CDI 的既定方法,但其用于首次或第二次 CDI 的治疗仍处于实验阶段。我们的目的是在真实的临床环境中研究 FMT 对第一次或第二次 CDI 的有效性。这项多中心丹麦队列研究纳入了 2019 年 6 月至 2023 年 2 月期间接受 FMT 治疗的首次或第二次 CDI 患者。主要结局是最后一次 FMT 治疗后 8 周相关性腹泻 (CDAD) 的治愈。次要结局包括首次 FMT 治疗后 1 周和 8 周的 CDAD 治愈率以及阳性检测后 90 天的死亡率。我们纳入了 467 名患者,其中 187 名 (40%) 患有首次 CDI。患者中位年龄为 73 岁(四分位数范围 [IQR],58-82 岁)。值得注意的是,167 人(36%)患有抗生素难治性 CDI,262 人(56%)患有严重 CDI,89 人(19%)患有暴发性 CDI。第一次 FMT 治疗后,第 1 周,353 名患者(76%;95% CI,71%–79%)实现了 CDAD 治愈。第 8 周,255 名患者(55%;95% CI, 50%–59%)保持持续效果。在最初没有效果的患者中,重复 FMT 治疗使 367 名患者的 CDAD 完全治愈(79%;95% CI,75%–82%)。 90 天死亡率为 10%(95% CI,8%–14%)。重复的 FMT 治疗在治疗第一次或第二次 CDI 患者方面表现出高效。在 CDI 治疗指南中转发 FMT 可以提高患者的生存率。 , 数字:
更新日期:2024-06-11
down
wechat
bug